published online as 40(3) 12] 1130 OBJECTIVES: The effects of age at diagnosis on the clinical characteristics of breast cancer and trends over time were investigated in Chinese women. METHODS: Data from 4211 women with pathologically confirmed primary breast cancer collected between 1999 and 2008 for a multicentre retrospective study were analysed according to age at diagnosis. RESULTS: Age at diagnosis ranged from 21 to 86 years, with a mean of 48.7 years, and was shown to be significantly related to tumour size, lymph node status, hormone receptor status and human growth factor receptor-2 status, but not to pathological type or tumour, node, metastasis stage. The age-corrected proportion of patients aged 50 -64 years at diagnosis increased significantly between 1999 and 2008. There was a significant difference in the agecorrected distribution of age at diagnosis in China compared with Western countries. CONCLUSIONS: Age at diagnosis is related to the clinical and pathological characteristics of breast cancer. The age at diagnosis in China increased over the decade from 1999 to 2008, but is still lower than in Western countries.
Introduction
Breast cancer is the most frequent cancer and the leading cause of cancer death in females, accounting for 23% (1.38 million) of total new cancer cases and 14% (458 400) of total cancer deaths in 2008, with a worldwide crude incidence of 41.4 / 100 000 per year. 1 Breast cancer is an age-related disease. The impact of age on the epidemiology, prognosis and treatment of breast cancer has been extensively reported. 2 Increasing age is the single most important risk factor for breast cancer after female gender. 3 In addition, age at diagnosis of < 35 years is a high-risk factor for relapse in nodenegative breast cancer. 4 There is a consensus that breast cancer is derived from two separate pathways -the early-onset/highrisk pathway and the late-onset/low-risk pathway, with most breast cancers being Age Interactions in Breast Cancer: an Analysis of a 10-year Multicentre Study in China HJ Yang, XF Yu, XM He et al. ' mixtures' of these two processes, with somatic mutations likely to account for the variations. 3 According to the GLOBOCAN 2008 database, 5 which covers cancer incidence, mortality and prevalence worldwide, the crude incidence of breast cancer in the Chinese female population is 26.2 / 100 000 per year; however, this may be an underestimate because of incomplete data. The incidence of breast cancer in China has increased sharply over recent decades, possibly as a result of lifestyle changes. 6 In large cities such as Shanghai, Beijing, Guangzhou and Chongqing, the incidence ranged from 43.8 / 100 000 to 60.1 / 100 000 per year in 2008, which is close to or even more than the mean incidence worldwide. Although the incidence of breast cancer overall is less than in Western countries, the increase in incidence indicates that breast cancer is becoming a major health problem in China.
Age interactions in breast cancer
Previous studies of the age distribution of breast cancer in China have each focused on only single traditional regions or districts; 7 -12 there are currently no studies characterizing the age distribution of breast cancer across the whole Chinese population. However, it has been reported that the Asian population may have a higher proportion of younger patients with breast cancer compared with Western countries: 4,13 -15 studies from Singapore, 13 Korea 14 and Japan 15 reported a mean age at diagnosis of 45 -49 years. The age of onset for breast cancer may be similar in China, 7, 8, 16 but may be affected by changes in reproductive patterns, physical activity and obesity. 16 -18 It is important to confirm age interactions in breast cancer in order to guide prevention and treatment of the disease; however, in many studies the effect of age has not been taken into account. 3 Rather than stratifying according to age at diagnosis to observe its full impact, investigators often adjust or match for age to negate its effects. This often limits the external validity of the data. 19 In most randomized clinical trials age is adjusted for or matched for within the inclusion criteria, so such studies are not able to show the full impact of age at diagnosis.
Our previous studies 20,21 established a methodology for random sampling of female breast cancer patients from all seven districts of China from 1999 to 2008. They reported on demographic characteristics, exposure to risk factors, imaging test results, pathological characteristics and therapeutic models. 20, 21 During the 10-year study period, the incidence and mortality of breast cancer increased rapidly, therefore these data may be helpful in clarifying the status of female breast cancer in China today and improving its management. In the present study, as part of a series of further analyses of the original data, the effect of age at diagnosis on stage and pathological characteristics was investigated in detail. Trends in the age distribution over the 10-year study period were also studied, and the overall age distribution of breast cancer was compared with that in other countries.
Patients and methods
Data from 4211 Chinese women with primary breast cancer from seven tertiary hospitals or medical centres representing each of the seven traditional districts of north, north-east, north-west, central, east, south and southwest China were included in the present study.
This study was a constitutive part of multicentre retrospective hospital-based research that was approved by the Cancer Foundation of China Institutional Review Board. 20 Patient consent was not required and all data were stripped of any patient identifiers.
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PATIENT DATA
In the multicentre study, 20 ≥ 50 cases of breast cancer in Chinese women were collected from each centre in a randomly selected month between March and December each year from 1999 to 2008 according to a prespecified enrolment scheme designed to avoid selection bias. The patient information was extracted to case report forms by two data input clerks at each site and was then sent for validation using EpiData software (http://www.epidata.dk/) to check for discrepancies. The methodology used is described in more detail in Li et al. 20 Information derived included demography, exposure to risk factors, clinical and histological variables such as age at diagnosis, tumour size, American Joint Committee on Cancer stage, 22,23 regional lymph node status, pathological type, and oestrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 status as determined by immunohistochemistry.
Patients were divided into four groups according to age at diagnosis: < 35 years, 35 -49 years, 50 -64 years and > 64 years.
DATA FROM OTHER COUNTRIES
The proportion of cases of breast cancer diagnosed within three of the age groups (< 50 years, 50 -64 years and > 64 years) was obtained from incidence data reported for the USA, 24 Europe, 5 Asian countries 5 and worldwide 5 over the 10-year study period. These data and those from the present study were then age-corrected for the demographics of the populations concerned using data from the National Bureau of Statistics of China, 25 the Surveillance, Epidemiology and End Results database, 24 and the GLOBOCAN 2008 database 5 as appropriate.
STATISTICAL ANALYSES
The χ 2 -test and Spearman's rank correlation test were used to evaluate differences and trends in categorical variables, such as lymph node status and human epidermal growth factor receptor-2 status, between the different age groups. Differences and trends in ordinal variables with more than two levels, including pathological type, tumour size, metastatic lymph node rate, regional lymph node status, stage, oestrogen receptor status and progesterone receptor status, were analysed using the χ 2 -test and Cochran-Armitage test. The Pearson χ 2 -test was used to determine differences in age-corrected incidence data for breast cancer between China and other countries. A P-value < 0.05 was considered to be statistically significant. All statistical analyses were performing using SPSS ® software version 16.0 (SPSS Inc., Chicago, IL, USA).
Results
Data from a total of 4211 Chinese women with breast cancer were available for analysis, accounting for 9.3% of breast cancer cases in China during the period from 1999 to 2008. 20 Age at diagnosis ranged from 21 to 86 years, with a mean age ± SD of 48.7 ± 10.5 years. Of the total, 295 (7.01%) patients were aged < 35 years at diagnosis, 2119 (50.32%) were aged 35 -49 years, 1446 (34.34%) were aged 50 -64 years, and 351 (8.34%) patients were aged > 64 years old.
CLINICAL CHARACTERISTICS AND AGE AT DIAGNOSIS
The clinical characteristics and biomarker status of the patients, according to age at diagnosis, are summarized in Table 1 . The majority of patients (3471/3999) were diagnosed with invasive ductal carcinoma, most of whom (2963 patients, 85.36%) were aged 35 -64 years at diagnosis.
Tumour size was significantly associated with age at diagnosis, with 42/224 (18.75%) HJ Yang, XF Yu, XM He et al. Only cases of invasive carcinoma were included in this analysis. TNM, tumour, node, metastasis; OR, oestrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor-2; NS, no statistically significant between-group differences (P > 0.05).
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of those aged < 35 years having a tumour size > 50 mm (χ 2 = 19.763, P = 0.003); however, tumour, node, metastasis (TNM) stage was not significantly related to age at diagnosis ( Table 1 ). The presence of metastatic lymph nodes was significantly related to age, with a greater proportion of patients aged < 35 years at diagnosis having lymph node metastases than older patients (χ 2 = 25.490, P < 0.001). In addition regional lymph node status was also significantly related to age at diagnosis (χ 2 = 27.534, P = 0.001). However, amongst patients with positive lymph nodes, the lymph node metastatic rate (the proportion of positive lymph nodes out of the total number of lymph nodes) showed no significant differences with age at diagnosis.
Complete hormone receptor test results were available for 3534 patients; age at diagnosis was related to hormone status subtype (χ 2 = 60.282, P < 0.001). Approximately 23% (694/3034) of patients for whom results were available were positive for human epidermal growth factor receptor-2, and human epidermal growth factor receptor-2 status was significantly related to age at diagnosis (χ 2 value = 10.727, P = 0.013).
CHANGES IN AGE AT DIAGNOSIS FROM 1999 TO 2008
The age-corrected percentage distributions of Chinese women with breast cancer for each year between 1999 and 2008, according to age at diagnosis, are given in Fig. 1 . Over the 10 years studied, the proportion of patients aged < 35 years at diagnosis decreased from 8.44% in 1999 to 5.03% in 2008, whereas the proportion of patients aged 50 -64 years increased from 29.53% in 1999 to 39.24% in 2008. This difference in age distribution over the study period was statistically significant (P = 0.002).
Comparing the data for Chinese women with breast cancer for the 5 years from 2004 to 2008 with the 5 years from 1999 to 2003 (Table 2) , the proportion of patients aged ≥ 50 years at diagnosis increased (from 39.17% to 45.45%), while the proportion of 
COMPARISON WITH OTHER COUNTRIES
Age-corrected percentage distributions of women according to age at diagnosis of breast cancer in China, Europe, USA, other Asian countries and worldwide are given in Table 2 . Patient distribution according to age of diagnosis of breast cancer in China showed a similar pattern to those for Korea and Asia overall, with the majority of patients in the youngest age group (< 50 years; 57.32% for China, 54.95% for Korea and 45.23% for Asia overall) and < 18% in the oldest age group (> 64 years). There were, however, statistically significant differences between the age-corrected percentages of patients according to age at diagnosis in China compared with Korea and Asia (P < 0.001 for both; Table 2 ).
The age-corrected distributions of women according to age at diagnosis of breast cancer in Western countries and Japan were the inverse of those in China, with the youngest age group (< 50 years) accounting for 19.78% in Europe, 24.31% in Japan and 24.71% in the USA and the oldest patient group (> 64 years) accounting for ≥ 35.92%; these data were all statistically significantly different from the data for China (P < 0.001; Table 2 ).
Discussion
The multicentre retrospective hospital-based research analysed in the present study is the first time that data describing the characteristics of female breast cancer representing the whole population in China has been available. Our previous studies have described the epidemiological and pathological characteristics of breast cancer 20, 21 and reported clear differences between Western countries and China. As part of a series of analyses of these data, the present study investigated the agecorrected percentage distribution of women with breast cancer, various clinical and pathological characteristics, and biomarker status, according to age at diagnosis, in 4211 Chinese women with breast cancer, and looked for trends in breast cancer distribution by age during the period from 1999 to 2008. Age at diagnosis was shown to be significantly related to tumour size, lymph node status, hormone receptor status and human growth factor receptor-2 status, but not to pathological type or TNM stage. Women aged < 50 years accounted for the majority of breast cancer cases in China from 1999 to 2008. In addition, over the 10year study period, the age at diagnosis in China rose.
In the USA, tumours with high-risk characteristics have been reported to be more common in younger women and, conversely, tumours with low-risk characteristics are more common in older women. 26 These characteristics may be common to female breast cancer in many areas of the world aside from Asian countries. Young premenopausal women have been reported to present more frequently with breast cancer marked by poor prognostic features such as a higher T stage, positive lymph nodes, endocrine nonresponsiveness and a high proliferating fraction compared with older women. 26 -32 In these studies, 'young' patients were defined as those aged 35 -40 years or younger. A literature search by Zhou and Recht 33 of the MEDLINE and CancerLit databases confirmed that women with breast cancer aged 35 -40 years or younger constituted a group of patients in whom age was an independent risk factor for higher rates of recurrence. In the present study, a higher proportion of Chinese women with breast cancer aged < 35 years at diagnosis had large tumours, metastatic lymph nodes and more advanced lymph node stage compared with older women. In contrast, the metastatic lymph node rate (positive lymph nodes / total lymph nodes) was not related to age at diagnosis. Hormone receptor status and human growth factor receptor-2 status were also found to be related to age. Tumour size and lymph node status are the two most important independent factors for breast cancer prognosis in all age groups. 34 The results of the present study suggest that lymph node status but not the metastatic lymph node rate is related to age at diagnosis. They also confirm previous studies 26 -32 in which breast cancer in young women in China has been shown to have similar characteristics to that in young women in other countries. Further analyses, taking into account the influence of menstrual status, are needed to assess the prognostic value of age at diagnosis in women with primary breast cancer across all age groups. 31 Whether age at diagnosis is an independent risk factor for breast cancer or not is an important issue to be resolved.
The present study has demonstrated that, in China, patients with a younger age at diagnosis (< 50 years) account for a higher proportion and older patients (> 64 years) for a lower proportion than in Japan, Europe and the USA. The distribution of age at diagnosis for breast cancer in China showed a similar pattern to that in Korea and Asia overall, although the percentages for the various age groups were significantly different from each other. The data for Asia were compiled from 48 countries from eastern Asia, south-east Asia, south central Asia and west Asia. The differences between these countries and China may reflect differences in the magnitude of background HJ Yang, XF Yu, XM He et al.
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breast cancer risk, differences in genetic background and differences in healthcare resource level. 21 Healthcare resources for breast cancer in many of these countries were greater than those available in China during the study period, which may partly explain the differences in percentages between China and Korea or Asia seen in the present study. Changes to Chinese governmental health insurance policies since 2004 may affect these differences in the future.
Further analysis comparing the 5-year periods of 1999 -2003 and 2004 -2008 showed that the age-corrected percentage distribution in China of age at diagnosis for breast cancer changed very little in China and the USA during these periods apart from a significant increase in the proportion of patients aged ≥ 50 years at diagnosis in China, with a corresponding decrease in the proportion aged < 50 years. This suggests that the difference in age distribution between these two populations may be due to factors that are not influenced by time, such as race or genetics. Changes in reproductive, lifestyle and possible environmental factors for women born in successive cohorts may have a cohort curvature effect on trends in the incidence of breast cancer. 35 This may explain to some degree why patients' age at diagnosis is increasing worldwide, even though the speed of change is very slow. 26, 35 The Chinese government has been gradually amending its health insurance policy since 2004. Increased numbers of elderly patients are, therefore, able to attend hospital for treatment of diseases, including malignant tumours, and this may be influencing the age at diagnosis. 21 This may have contributed to the significant increase in the proportion of women with breast cancer aged ≥ 50 years at diagnosis in China.
In conclusion, the present study shows that age at diagnosis is an important factor in the development of breast cancer and is related to clinical characteristics such as tumour size, lymph node status, hormone receptor status and human growth factor receptor-2 status. The observed hospitalbased age interactions in breast cancer suggest that younger patients are more likely to have large tumours and metastatic lymph nodes and to be positive for human growth factor receptor-2, whereas older patients are less likely to be negative for oestrogen and progesterone receptors. The distribution pattern of age at diagnosis in China is similar to that in other Asian countries, but is different to that in Western countries. However, trends in the percentage distribution of breast cancer by age at diagnosis in China may indicate that the pattern of breast cancer development has been moving subtly towards an ageing/lowrisk mode. Further studies focused on the relationship between age and pathological characteristics whilst eliminating the influence of menstrual status may help to solve the issue of whether age at diagnosis is an independent risk factor for breast cancer.
